Literature DB >> 33901731

Randomized peptide assemblies for enhancing immune responses to nanomaterials.

Nicole L Votaw1, Lauren Collier1, Elizabeth J Curvino1, Yaoying Wu1, Chelsea N Fries1, Madison T Ojeda1, Joel H Collier2.   

Abstract

Biomaterials capable of inducing immune responses with minimal associated inflammation are of interest in applications ranging from tissue repair to vaccines. Here we report the design of self-assembling randomized polypeptide nanomaterials inspired by glatiramoids, an immunomodulatory class of linear random copolymers. We hypothesized that peptide self-assemblies bearing similar randomized polypeptides would similarly raise responses skewed toward Type 2 immunity and TH2 T-cell responses, additionally strengthening responses to co-assembled peptide epitopes in the absence of adjuvant. We developed a method for synthesizing self-assembling peptides terminated with libraries of randomized polypeptides (termed KEYA) with good batch-to-batch reproducibility. These peptides formed regular nanofibers and raised strong antibody responses without adjuvants. KEYA modifications dramatically improved uptake of peptide nanofibers in vitro by antigen presenting cells, and served as strong B-cell and T-cell epitopes in vivo, enhancing immune responses against epitopes relevant to influenza and chronic inflammation while inducing a KEYA-specific Type 2/TH2/IL-4 phenotype. KEYA modifications also increased IL-4 production by T cells, extended the residence time of nanofibers, induced no measurable swelling in footpad injections, and decreased overall T cell expansion compared to unmodified nanofibers, further suggesting a TH2 T-cell response with minimal inflammation. Collectively, this work introduces a biomaterial capable of raising strong Type 2/TH2/IL-4 immune responses, with potential applications ranging from vaccination to tissue repair.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epitope; Glatiramer acetate; Nanofiber; Self-assembling; Supramolecular; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 33901731      PMCID: PMC8163017          DOI: 10.1016/j.biomaterials.2021.120825

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   15.304


  63 in total

1.  Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses.

Authors:  J Alexander; M F del Guercio; A Maewal; L Qiao; J Fikes; R W Chesnut; J Paulson; D R Bundle; S DeFrees; A Sette
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

2.  Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus.

Authors:  Brian M Friedrich; David W C Beasley; Jai S Rudra
Journal:  Vaccine       Date:  2016-09-23       Impact factor: 3.641

3.  Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models.

Authors:  Alberto Grandi; Laura Fantappiè; Carmela Irene; Silvia Valensin; Michele Tomasi; Simone Stupia; Riccardo Corbellari; Elena Caproni; Ilaria Zanella; Samine J Isaac; Luisa Ganfini; Luca Frattini; Enrico König; Assunta Gagliardi; Simona Tavarini; Chiara Sammicheli; Matteo Parri; Guido Grandi
Journal:  Front Oncol       Date:  2018-10-26       Impact factor: 6.244

4.  Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells.

Authors:  Pedro L Vieira; Heleen C Heystek; Jan Wormmeester; Eddy A Wierenga; Martien L Kapsenberg
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

5.  Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.

Authors:  Jishu Wei; Wentao Gao; Junli Wu; Kai Meng; Jingjing Zhang; Jianmin Chen; Yi Miao
Journal:  Cancer Biother Radiopharm       Date:  2008-02       Impact factor: 3.099

6.  A universal epitope-based influenza vaccine and its efficacy against H5N1.

Authors:  Y Adar; Y Singer; R Levi; E Tzehoval; S Perk; C Banet-Noach; S Nagar; R Arnon; T Ben-Yedidia
Journal:  Vaccine       Date:  2009-02-13       Impact factor: 3.641

7.  This paper is the winner of an SFB Award in the Hospital Intern, Residency category: Peptide biomaterials raising adaptive immune responses in wound healing contexts.

Authors:  Yalini Vigneswaran; Huifang Han; Roberto De Loera; Yi Wen; Xing Zhang; Tao Sun; Carolina Mora-Solano; Joel H Collier
Journal:  J Biomed Mater Res A       Date:  2016-05-26       Impact factor: 4.396

8.  Co-assembling peptides as defined matrices for endothelial cells.

Authors:  Jangwook P Jung; Arun K Nagaraj; Emily K Fox; Jai S Rudra; Jason M Devgun; Joel H Collier
Journal:  Biomaterials       Date:  2009-02-08       Impact factor: 12.479

9.  Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice.

Authors:  Hai-Bo Li; Jin-Yong Zhang; Ya-Fei He; Li Chen; Bin Li; Kai-Yun Liu; Wu-Chen Yang; Zhuo Zhao; Quan-Ming Zou; Chao Wu
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

Review 10.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
View more
  1 in total

1.  Interaction Between Ropivacaine and a Self-Assembling Peptide: A Nanoformulation for Long-Acting Analgesia.

Authors:  Fei Peng; Jing Liu; Yujun Zhang; Guoyan Zhao; Deying Gong; Liu He; Wensheng Zhang; Feng Qiu
Journal:  Int J Nanomedicine       Date:  2022-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.